Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar

Discloses Phase I Details And Phase III Plans Ahead Of Filings In EU And US

 
• By David Wallace
  
Low Price Dial Green Orange Red
Prestige Biopharma believes it can compete on price in the Humira market • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products